A rare, naturally pluripotent cell.
Discovered in 2010 at Tohoku University, Muse cells are a sparse subpopulation of mesenchymal stem cells, roughly one to three percent of an MSC pool. They carry the pluripotency marker SSEA-3, survive conditions that kill ordinary cells, and migrate to sites of physical distress on their own.
In plain terms: cells that survive when nothing else does, and rebuild what they find broken into the tissue it was meant to be.
How Muse cells compare.
The standard alternatives in regenerative medicine, set against the properties patients and clinicians actually weigh.
| Property | Muse | UC-MSC | Embryonic (hESC) | Induced (iPSC) |
|---|---|---|---|---|
| Source | Adult mesenchymal tissue | Umbilical cord (Wharton's jelly) | Donated embryos | Reprogrammed somatic cells |
| Pluripotency | All three germ layers | Mesoderm only | All three germ layers | All three germ layers |
| Tumorigenic risk | Minimal — none reported in human trials | None reported | Documented teratoma formation | Documented teratoma formation |
| Injury-site homing | Yes — S1P-guided | Limited | No | No |
| Abundance | 1–3% of MSC pool | Abundant | Limited | Engineerable |
| Regulatory status | Investigational (MX / Japan) | COFEPRIS-regulated (MX) | FDA-restricted | FDA-restricted |
Properties summarised from peer-reviewed sources. View references →
Muse cells, by the numbers.
Four anchor facts, each tied to its primary source.
of the standard MSC pool is Muse-positive.
Kuroda Y, et al. Unique multipotent cells in adult human mesenchymal cell populations. PNAS 2010.
First isolated at Tohoku University by the Dezawa lab.
Dezawa M, et al. Multilineage-differentiating stress-enduring (Muse) cells. Original report →
Surface marker used to identify and sort Muse cells from MSC pools.
Wakao S, et al. Multilineage-differentiating stress-enduring (Muse) cells. PNAS 2011.
Tumors reported across published Muse-cell human trials to date.
Multiple Phase I/II trials, 2018–2024. Trial summary →
How Muse cells reach injury.
The S1P-guided homing mechanism, traced from infusion to integration.
-
01
Infusion
Muse cells enter circulation by IV. No targeted delivery is required: the bloodstream is the delivery route.
Wakao S, et al. PNAS 2011. -
02
S1P gradient detection
Damaged tissue releases sphingosine-1-phosphate (S1P). Muse cells express the S1P receptor and follow the gradient toward its highest concentration.
Yamada Y, et al. Biochem Biophys Res Commun, 2018. -
03
Migration + integration
Muse cells concentrate at the injury site, differentiate into the resident tissue type (cartilage, neuron, hepatocyte), and integrate without forming teratomas.
Kuroda Y, et al. PNAS 2010 (mechanism); Phase I/II trials 2018–2024 (safety).
Repair that meets the tissue where it is.
Standard mesenchymal cells modulate inflammation and signal repair, but rely on the body to do the building. Muse cells contribute that signaling and integrate directly into the damaged structure, behaving like the tissue they replace.
-
01
Direct integration, not just signaling.
Standard UC-MSCs orchestrate repair through paracrine signaling and fade. Muse cells differentiate into the resident cell type at the injury site and remain as functional tissue.
-
02
Tissue-specific adaptation.
Cartilage in a joint. Neurons in a stroke lesion. Hepatocytes in a damaged liver. Muse cells adopt the cell type appropriate to where they arrive, not a fixed lineage.
-
03
Stress-tolerant survival.
Originally isolated by what survived under severe cellular stress. That resilience translates to clinical use: more cells reach the injury alive, more integrate, fewer are lost in transit.